Redeye returns with a broadly unchanged outlook following GomSpace's H1 2026 report, which showed co...
Redeye comments on Oncopeptides' Q2 report. Sales amounted to SEK31.
* Positivt vetenskapligt utlåtande från EFSA * Chr.
Kentimas Q2 var något svagare än väntat. Omsättningen ökade 5 procent till 19,0 mkr, medan högre pro...
* Emerging from an abnormal regulatory downturn as European carbon markets normalise and US profitab...
Final H1 results show that LAIQON's enlarged platform has reached a clear earnings inflection.
Systemair continues to show healthy growth and improving profitability with 6% organic growth and EB...
Bittium announced on Friday that it has started to change negotiations in its smallest business segm...
* Sports margin flat y-o-y as FIFA World Cup... * .
mResell levererade fortsatt stark tillväxt i Q2’26.
Redeye notes that Sivers' Q2 2026 report confirmed a deliberately softer quarter, with net sales of ...
Lytix Biopharma's second-quarter 2026 report was dominated by the FDA's feedback that it raises no o...
Based on a press release, we note that the founder and Chairman of the Board of Bactiguard, Thomas v...
Kvartalet var i stort sett i linje med våra förväntningar avseende intäkter och bruttoresultat, meda...
Mangold återupptar bevakning av sensorteknikbolaget JonDeTech Sensors.
Following the strong semaglutide data reported earlier this year, Nanexa’s Q2 update points to conti...
Redeye updates its estimates following Fable Media Group's Q2 2026 report, which we view as a strong...
Redeye provides a research update following the Q2 report recently published by OncoZenge.
* H1 above expectations, driven by strong margins and cost control * Soft autumn intake guidance lea...
Redeye states that the Q2 report showed a soft quarter on headline figures, largely as flagged by ma...